Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feriel Azibani

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Critical Care (London, England)|August 1, 2025
Targeting high circulating dipeptidyl peptidase 3 in circulatory failureAdrien Picod, Feriel Azibani, Veli-Pekka Harjola, et al.
European Journal of Heart Failure|September 1, 2019
Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trialKoji Takagi, Alice Blet, Bruno Levy, et al.
Journal of Cardiac Failure|May 2, 2024
High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH TrialAdrien Picod, Hugo Nordin, Dominik Jarczak, et al.
Hypertension (Dallas, Tex. : 1979)|February 9, 2024
Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin PeptidesAdrien Picod, Sandrine Placier, Magali Genest, et al.
ESC Heart Failure|November 28, 2020
N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trialMahmoud U Sani, Albertino Damasceno, Beth A Davison, et al.
Hypertension (Dallas, Tex. : 1979)|May 2, 2012
Aldosterone inhibits antifibrotic factors in mouse hypertensive heartFeriel Azibani, Ludovic Benard, Saskia Schlossarek, et al.
Molecular Therapy. Nucleic Acids|March 4, 2018
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular DystrophyFeriel Azibani, Astrid Brull, Ludovic Arandel, et al.
Cardiorenal Medicine|August 12, 2024
Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based ApproachLouis Boutin, Sabri Soussi, Angèle Garcia Lavello, et al.
Open Forum Infectious Diseases|January 5, 2023
Long-Term Follow-up of Human Immunodeficiency Virus-Associated Pulmonary Hypertension: Clinical Features and Survival Outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO)Friedrich Thienemann, Patrick D M C Katoto, Feriel Azibani, et al.
Frontiers in Medicine|December 19, 2022
Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: <i>Post-hoc</i> analyses of the phase II adrenomedullin and outcome in septic shock 2 trialDirk van Lier, Adrien Picod, Gernot Marx, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Critical Care (London, England)|August 1, 2025
Targeting high circulating dipeptidyl peptidase 3 in circulatory failureAdrien Picod, Feriel Azibani, Veli-Pekka Harjola, et al.
European Journal of Heart Failure|September 1, 2019
Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trialKoji Takagi, Alice Blet, Bruno Levy, et al.
Journal of Cardiac Failure|May 2, 2024
High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH TrialAdrien Picod, Hugo Nordin, Dominik Jarczak, et al.
Hypertension (Dallas, Tex. : 1979)|February 9, 2024
Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin PeptidesAdrien Picod, Sandrine Placier, Magali Genest, et al.
ESC Heart Failure|November 28, 2020
N-terminal pro BNP and galectin-3 are prognostic biomarkers of acute heart failure in sub-Saharan Africa: lessons from the BAHEF trialMahmoud U Sani, Albertino Damasceno, Beth A Davison, et al.
Hypertension (Dallas, Tex. : 1979)|May 2, 2012
Aldosterone inhibits antifibrotic factors in mouse hypertensive heartFeriel Azibani, Ludovic Benard, Saskia Schlossarek, et al.
Molecular Therapy. Nucleic Acids|March 4, 2018
Gene Therapy via Trans-Splicing for LMNA-Related Congenital Muscular DystrophyFeriel Azibani, Astrid Brull, Ludovic Arandel, et al.
Cardiorenal Medicine|August 12, 2024
Galectin-3 and Soluble CD146 Identify Cardiorenal Injuries in Severe Burn Patients: A Biomarker-Based ApproachLouis Boutin, Sabri Soussi, Angèle Garcia Lavello, et al.
Open Forum Infectious Diseases|January 5, 2023
Long-Term Follow-up of Human Immunodeficiency Virus-Associated Pulmonary Hypertension: Clinical Features and Survival Outcomes of the Pan Africa Pulmonary Hypertension Cohort (PAPUCO)Friedrich Thienemann, Patrick D M C Katoto, Feriel Azibani, et al.
Frontiers in Medicine|December 19, 2022
Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: <i>Post-hoc</i> analyses of the phase II adrenomedullin and outcome in septic shock 2 trialDirk van Lier, Adrien Picod, Gernot Marx, et al.
Pageof 6